On December 6, ADVI Health’s strategic analytics, value and economics (SAVEs) solution team had a poster presentation featured at the American Society of Hematology (ASH)’s Annual Meeting and Exposition in Orlando, FL.

The abstract, “Transfusion burden among older US patients with relapsed FLT3-mutated Acute Myeloid Leukemia treated with gilteritinib: A Medicare claims-based cohort study,” was authored by ADVI expert Peter Kardel, vice president of strategic analytics, value and economics (SAVEs), alongside colleagues from Duke University School of Medicine and Astellas and analyzes transfusion burden among Medicare beneficiaries with relapsed AML receiving gilteritinib.

Read the full abstract.